Scott Antonia
Overview
Explore the profile of Scott Antonia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
11343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clarke J, Simon G, Mamdani H, Gu L, Herndon 2nd J, Stinchcombe T, et al.
Nat Commun
. 2025 Jan;
16(1):93.
PMID: 39747856
GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b...
2.
Peters P, Whitaker R, Lim F, Russell S, Bloom E, Pollara J, et al.
Neoplasia
. 2024 Sep;
57:101056.
PMID: 39276533
Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor...
3.
Freeman C, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4575-4585.
PMID: 37735756
Purpose: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded with full-length survivin (Ad-S), with mutations neutralizing its antiapoptotic function, could safely generate an immune...
4.
Nadal E, Saleh M, Aix S, Ochoa-de-Olza M, Patel S, Antonia S, et al.
BMC Cancer
. 2023 Jul;
23(1):708.
PMID: 37507657
Background: In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib...
5.
McCutcheon S, Swartz A, Brown M, Barrera A, McRoberts Amador C, Siklenka K, et al.
bioRxiv
. 2023 May;
PMID: 37205457
The clinical response to adoptive T cell therapies is strongly associated with transcriptional and epigenetic state. Thus, technologies to discover regulators of T cell gene networks and their corresponding phenotypes...
6.
Naidoo J, Antonia S, Wu Y, Cho B, Thiyagarajah P, Mann H, et al.
J Thorac Oncol
. 2023 Feb;
18(5):657-663.
PMID: 36841540
Introduction: Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the...
7.
Bodd M, Locke S, Wolf S, Antonia S, Crawford J, Hartman J, et al.
Lung Cancer
. 2022 Nov;
175:17-26.
PMID: 36442383
Objectives: There are limited real-world data about patient-reported outcomes with immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe patient-reported distress and clinical outcomes with IO-based treatments or...
8.
Tcyganov E, Sanseviero E, Marvel D, Beer T, Tang H, Hembach P, et al.
Cancer Cell
. 2022 Oct;
40(10):1173-1189.e6.
PMID: 36220073
Cancer immunotherapy often depends on recognition of peptide epitopes by cytotoxic T lymphocytes (CTLs). The tumor microenvironment (TME) is enriched for peroxynitrite (PNT), a potent oxidant produced by infiltrating myeloid...
9.
Prabhakaran S, Gatenbee C, Robertson-Tessi M, West J, Beg A, Gray J, et al.
Patterns (N Y)
. 2022 Jul;
3(7):100523.
PMID: 35845830
Understanding the complex ecology of a tumor tissue and the spatiotemporal relationships between its cellular and microenvironment components is becoming a key component of translational research, especially in immuno-oncology. The...
10.
Ding S, Hsu C, Wang Z, Natesh N, Millen R, Negrete M, et al.
Cell Stem Cell
. 2022 May;
29(6):905-917.e6.
PMID: 35508177
Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions...